Injective (INJ) has stabilized at $5.11 following a sharp decline in October, marking a recent 3% increase. The protocol executed $39.5 million in token buybacks in November, effectively reducing its circulating supply. Additionally, Injective's RWA perpetual market volume surpassed $6 billion, indicating robust trading activity. Market analysts suggest that if INJ can break through the $7 resistance level, its price target for December could range between $10 and $14, reflecting potential bullish momentum.